Mortality and Health Outcomes in Multiple Sclerosis Patients

Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system associated with a tangible reduction in life expectancy and a spectrum of health outcomes that extend beyond neurological impairment. Overall mortality in MS remains elevated relative to the general population, driven by both disease-related mechanisms and secondary complications such as infections, cardiovascular events and aspiration pneumonias. Disability progression, often quantified by the Expanded Disability Status Scale (EDSS), correlates strongly with risk of death and serious adverse events. Comorbid conditions—including depression, cardiovascular disease and impaired respiratory function—further modulate survival and quality of life. Improvements in diagnostic accuracy, the arrival of more potent disease-modifying therapies (DMTs) and enhanced supportive care have contributed to a gradual decline in excess mortality over recent decades. Nonetheless, life expectancy remains shortened by several years, underscoring the need for early intervention, vigilant monitoring of comorbidities and equitable access to emerging treatments across diverse populations.

Research from Nature Portfolio

Recent studies have illuminated the role of immune components and treatment pathways in determining health outcomes. One investigation used high-dimensional mass cytometry to characterise innate immune cell subsets in patients receiving DMTs, revealing specific myeloid phenotypes that predict both cellular and humoral responses to vaccination. This work suggests that monitoring of myeloid cell markers could inform personalised vaccination strategies and infection risk management in MS. A complementary real-world analysis explored patterns of DMT initiation among immigrant and long-term resident groups within a universal healthcare system. It demonstrated that socio-economic status influences the timing and likelihood of therapy uptake, with potential downstream effects on disability progression and mortality. Together, these studies underscore the interplay between immune modulation, treatment access and long-term outcomes in MS cohorts.

Mortality and Health Outcomes in Multiple Sclerosis Patients publication trend

The graph below shows the total number of articles in mortality and health outcomes in multiple sclerosis patients across all publications each year (not limited to Nature Index journals).

Technical terms

Expanded Disability Status Scale (EDSS): a quantitative measure of neurological impairment in MS patients, ranging from 0 (normal neurological examination) to 10 (death due to MS).

Standardised Mortality Ratio (SMR): the ratio of observed deaths in a study population to expected deaths based on general population rates, adjusted for age and sex.

Excess Death Rate (EDR): the absolute difference between observed and expected death rates per unit population over a defined timeframe.

Disease-Modifying Therapies (DMTs): pharmacological agents intended to reduce relapse frequency and slow the progression of disability in MS by altering immune system activity.

References

1. Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases. Nature Communications (2023).
2. Multiple sclerosis disease-modifying drug use by immigrants: a real-world study. Scientific Reports (2023).
3. Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study. Journal of Neurology (2025).
4. Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Brain Communications (2023).
5. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. Journal of Neurology (2014).
6. Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study. Brain Behavior & Immunity - Health (2022).